PATIENT REPORTED OUTCOMES IN THE DIAGNOSIS AND TREATMENT OF LYMPHOMA
Dr Elizabeth Goodall,
Haematologist and PhD student
Austin Health, Olivia Newton-John Cancer Research Institute & Monash Health, Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne | February 2025
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
After completing her undergraduate degree in Medical Sciences at La Trobe University she went onto complete an Honours degree in malaria research before enrolling in Medicine at Monash University, Gippsland, Victoria in Australia.
Following medical school, she trained at Austin Health and successfully completed both clinical and laboratory haematology programs before moving to a lymphoma clinical trials fellowship at Monash Health. This fellowship provided essential clinical skills and has fostered a life-long interest in improving patient access to trials, finding ways to better select therapies for patients with blood cancers and learning more about the patient’s experience throughout treatment.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.
This has led to her PhD on Patient Reported Outcomes (PROs) which will focus on the accurate documentation of the patient experience and learn how best to include this data for future clinical trial design, an essential component of obtaining excellent treatment outcomes. For this work she is the 2025 recipient of the Haematology Society of Australia and New Zealand and the Leukaemia Foundation New Investigator PhD Scholarship which will provide invaluable support throughout the PhD.
-
Development of novel analytical and diagnostic tools using nanotechnology and microfluidics
Dr Alain Wuethrich is an NHMRC Emerging Leader fellow and ARC DECRA awardee at the Australian Institute for Bioengineering and Nanotechnology.
Hailing from Switzerland, research focuses on the development of novel analytical and diagnostic tools that harness nanotechnology and microfluidics; two rapidly growing fields with high potential to provide diagnostic solutions needed for precision medicine.
-
Dr Zarina Greenberg
RESEARCH IN BRAIN COMPUTER INTERFACE
@ SYNCHRON
MELBOURNE, VICTORIA, AUSTRALIA -
Better biomarkers for predicting the incidence of having atherosclerosis and heart attack
Assoc Prof Bursill is a vascular biologist with interests and expertise in vascular inflammation, atherosclerosis and angiogenesis. She completed her PhD at The University of Adelaide in lipid metabolism then headed to Oxford University for five years to undergo a postdoctoral post in the Departments of Cardiovascular Medicine and Pathology. Her postdoctoral time triggered her interest in the mechanisms that cause atherosclerosis and in particular the role of small inflammatory proteins called chemokines.
